Market Pressure From Employers and Consumers By early 2025: - 60% of large employers had added GLP-1 coverage - GLP-1 spending became one of the largest drivers of rising employer healthcare premiums - Companies began pushing for greater price transparency At the same time: - Consumer adoption accelerated 1 in 8 women and 1 in 20 men had used or were using a GLP-1 - GLP-1s went from a niche therapy to a central pillar of chronic disease management These changes were necessary because the millions of Americans living with obesity couldn't afford GLP-1 medications, even though they stood to benefit the most
v., Jerzabek G., Engelbart K., Kuhl H., Fraser H
Tirzepetide is a dual GLP-1/GIP agonist
IGF-1 LR3 differs significantly from growth hormone secretagogues such as CJC-1295 or Ipamorelin
The blistering phase lasts 3 to 5 days, followed by extensive peeling that can continue for two weeks or more
Consistent with this finding, postmortem studies have reported markedly downregulated gene expression of antioxidant enzymes such as SOD1 and glutathione S-transferase in the hippocampus of BD patients, a finding that may relate to bipolar depression as the dominant phase [56]
